林奇综合征的分子病理学
本文综述林奇综合征(LS)的分子病理学,LS由MMR基因(MLH1、MSH2、MSH6、PMS2)的遗传致病变异引起,估计患病率在1/100至1/180之间。文章整合基因变异数据库、PLSD、CCFR及病理和免疫学研究,阐述变异解读标准、MMR在凋亡控制中的功能、癌症风险、结直肠和子宫内膜肿瘤的发生机制及免疫系统的关键作用,并讨论结直肠癌的三条发生途径及结肠镜监测的局限性和免疫检查点阻断治疗的疗效。
要点
- LS由MMR基因遗传致病变异引起,估计患病率1/100至1/180。
- 结直肠癌在LS中可经三条途径发生,包括平坦型黏膜内病变,取决于受累MMR基因。
- 免疫自身免疫和免疫编辑过程限制LS肿瘤发展,解释免疫检查点阻断在MMR缺陷肿瘤中的疗效。
核心结论
- LS的分子病理学进展包括基因变异解读标准、MMR在凋亡控制中的功能、癌症风险定义及结直肠和子宫内膜肿瘤发生机制。
- LS结直肠癌可经三条途径发生,包括平坦型黏膜内病变,取决于 underlying 受累MMR基因,提示结肠镜监测的局限性。
- 自身免疫和免疫编辑过程从根本上限制LS肿瘤发展,并解释免疫检查点阻断治疗在MMR缺陷肿瘤中的疗效。
研究设计与样本
- 综述,整合国际胃肠遗传性癌症学会MMR基因变异数据库、前瞻性林奇综合征数据库(PLSD)、结肠癌家族登记(CCFR)及病理和免疫学研究。
主要发现
- LS估计患病率在1/100至1/180之间。
- LS结直肠癌可沿三条途径发展,包括平坦型黏膜内病变,取决于 underlying 受累MMR基因。
- 免疫系统在LS肿瘤发生中起关键作用,自身免疫和免疫编辑过程限制肿瘤发展。
临床怎么用
- LS结直肠癌可经平坦型黏膜内病变发生,提示结肠镜监测存在局限性,需其他抗癌预防措施。
- MMR缺陷肿瘤对免疫检查点阻断治疗有效,基于免疫编辑和自身免疫机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lynch syndrome (LS) is characterised by predisposition to colorectal, endometrial, and other cancers and is caused by inherited pathogenic variants affecting the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2. It is probably the most common predisposition to cancer, having an estimated prevalence of between 1/100 and 1/180. Resources such as the International Society for Gastrointestinal Hereditary Cancer's MMR gene variant database, the Prospective Lynch Syndrome Database (PLSD), and the Colon Cancer Family Register (CCFR), as well as pathological and immunological studies, are enabling advances in the understanding of LS. These include defined criteria by which to interpret gene variants, the function of MMR in the normal control of apoptosis, definition of the risks of the various cancers, and the mechanisms and pathways by which the colorectal and endometrial tumours develop, including the critical role of the immune system. Colorectal cancers in LS can develop along three pathways, including flat intramucosal lesions, which depend on the underlying affected MMR gene. This gives insights into the limitations of colonoscopic surveillance and highlights the need for other forms of anti-cancer prophylaxis in LS. Finally, it shows that the processes of autoimmunisation and immunoediting fundamentally constrain the development of tumours in LS and explain the efficacy of immune checkpoint blockade therapy in MMR-deficient tumours. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
- Cerretelli G, Ager A, Arends MJ, et al. Molecular pathology of Lynch syndrome. J Pathol. 2020. PMID: 32141610. doi:10.1002/path.5422
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。